Tocilizumab in HIV patient with severe COVID-19: case report

A 73-year-old male patient who had a history of Human Immunodeficiency Virus (HIV) infection for over 20 years was diagnosed with SARS-CoV-2 infection. The patient was admitted to the Intensive Care Unit (ICU), where he remained for 25 days, due to a severe condition. Intubation, hemodialysis, and t...

Full description

Saved in:

Bibliographic Details
Published in:	AIDS research and therapy Vol. 18; no. 1; p. 73
Main Authors:	Bertozzi, Pedro Vieira, de Oliveira Vicente, Amanda, Pereira, Amanda Siqueira, de Sant'Ana, Joao Pedro Espinha, Mano, Rafaela Braga Cabrera, Jorge, Luciana Souza, da Silva Sardenberg, Rodrigo Afonso
Format:	Journal Article
Language:	English
Published:	England BioMed Central Ltd 16-10-2021 BioMed Central BMC
Subjects:	Aged Analysis Antibodies, Monoclonal, Humanized - therapeutic use Antiretroviral agents Care and treatment Case Report Case reports Coinfection Comorbidity Coronaviruses COVID-19 COVID-19 Drug Treatment Diagnosis Health aspects Hemodialysis Highly active antiretroviral therapy HIV HIV Infections - complications HIV Infections - drug therapy HIV patients Homeostasis Human immunodeficiency virus Humans Hypertension Immune response Immune system Intubation Lymphocytes Male Males Monoclonal antibodies Mortality Patients Recovery Risk analysis Risk factors Ritonavir Severe acute respiratory syndrome coronavirus 2 Tocilizumab Tracheostomy Viral diseases Brazil COVID-19 Case report Coinfection HIV Tocilizumab
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	A 73-year-old male patient who had a history of Human Immunodeficiency Virus (HIV) infection for over 20 years was diagnosed with SARS-CoV-2 infection. The patient was admitted to the Intensive Care Unit (ICU), where he remained for 25 days, due to a severe condition. Intubation, hemodialysis, and tracheostomy were necessary to maintain homeostasis. In addition to regular treatment with etravirine, dolutegravir, darunavir, and ritonavir for highly active antiretroviral therapy, the patient received tocilizumab, which showed a great recovery in the patient's condition. The patient had several risk factors, such as male gender, age > 70 years, and arterial hypertension. The use of tocilizumab was of great importance in the patient's recovery since the drug increased his immune response, which is deficient, due to HIV infection.
Bibliography:	ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3
ISSN:	1742-6405 1742-6405
DOI:	10.1186/s12981-021-00404-5